Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CTH | P32929 | 1/20 | 0.32 |
| ▸ | CBS | P35520 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | CPB1 | P15086 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | BHMT | Q93088 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13241287 | 0.75 | HPGD (0.40) | KMT2A | |
| SCHEMBL1106832 | 0.69 | CPB1 (0.61) | ALOX15BLMPMP22KMT2ACPB1 | |
| SCHEMBL1106828 | 0.68 | ALOX15 (0.40) | ALOX15BLMPMP22KMT2ACPB1 | |
| SCHEMBL1106817 | 0.66 | TDP1 (0.45) | ALOX15BLMPMP22KMT2ACPB1 | |
| SCHEMBL22681123 | 0.65 | — | — | |
| SCHEMBL14157743 | 0.64 | EPHX1 (0.37) | ALOX15BLMPMP22KMT2ACYP1A2 | |
| SCHEMBL163253 | 0.64 | TSHR (0.72) | ALOX15BLMPMP22KMT2ATSHR | |
| SCHEMBL28364927 | 0.63 | BHMT (0.48) | KMT2ATSHRCYP1A2BHMT | |
| Ammonia Solution, Strong SCHEMBL11526981 | 0.62 | CTH (0.43) | TSHRCTHCBSTHPOTHRB | |
| SCHEMBL1106829 | 0.62 | LMNA (0.74) | ALOX15BLMPMP22KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153716-B2 | Dispersant for an aqueous dispersion of positively charged or chargeable solid particulates which comprises a compound having an anchoring moiety linked to a polymeric hydrophilic moiety; inkjet recording element | EASTMAN KODAK COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-8063132-B2 | Coating composition comprising boehmite particles and one or more dispersants and a method of coating a substrate using said coating composition | EASTMAN KODAK COMPANY (US) | 2011-11-22 | — | — | US | disclosed |
| US-20080145546-A1 | Dispersant For Reducing Viscosity Of Particulate Solids | FPC INC. | 2008-06-19 | — | — | US | disclosed |
| US-20080090012-A1 | Aqueous boehmite particles of a hydrophilic polymer having a linked anchoring moiety which contains acid(s) and/or hydroxy(s); the polymeric moiety has a lower affinity for a boehmite surface than the anchoring moiety; mercaptosuccinic acid-modified polyacrylamide; ink jet; paper coating; gloss porousity | KODAK PHILIPPINES LTD. | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090012-A1 | Aqueous boehmite particles of a hydrophilic polymer having a linked anchoring moiety which contains acid(s) and/or hydroxy(s); the polymeric moiety has a lower affinity for a boehmite surface than the anchoring moiety; mercaptosuccinic acid-modified polyacrylamide; ink jet; paper coating; gloss porousity | CD44, MPST, BHMT2 | ALOX15 1032/4885BLM 2315/4885PMP22 3459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.